Wednesday, April 22

Browsing: Zenocutuzumab

Diagnosis

FDA Receives sBLA for Zenocutuzumab in Advanced NRG1+ Cholangiocarcinoma

By NewsCancerApril 15, 20260

The FDA has received a supplemental Biologics License Application (sBLA) for zenocutuzumab-zbco (Bizengri) for the treatment of patients with advanced…

Diagnosis

Zenocutuzumab: An Effective Option Beyond Progression in NRG1+ NSCLC?

By NewsCancerMarch 7, 20260

NRG1 fusions are a clinically meaningful oncogenic driver to target in non–small cell lung cancer (NSCLC) with zenocutuzumab-zbco (Bizengri), even…

Treatments

New Zenocutuzumab Findings Provide Hope for Targeting Rare NSCLC Subtypes

By NewsCancerMarch 5, 20260

At the 2026 International Association for the Study of Lung Cancer (IASLC) Targeted Therapies of Lung Cancer (TTLC) Meeting, Zhaohui…

► Necessary Cookies Always Active

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.

What's Hot

AACR in 30 Seconds: Revolution Medicines data, NCI director, wildfires

HDAC8 inhibition targets STAT3–MYC axis and synergizes with Venetoclax in KMT2A-rearranged acute myeloid leukemia

Mastectomy, ET Linked to Lower LRR in Young Populations With Breast Cancer

Browsing: Zenocutuzumab

FDA Receives sBLA for Zenocutuzumab in Advanced NRG1+ Cholangiocarcinoma

Zenocutuzumab: An Effective Option Beyond Progression in NRG1+ NSCLC?

New Zenocutuzumab Findings Provide Hope for Targeting Rare NSCLC Subtypes

AACR in 30 Seconds: Revolution Medicines data, NCI director, wildfires

HDAC8 inhibition targets STAT3–MYC axis and synergizes with Venetoclax in KMT2A-rearranged acute myeloid leukemia

Mastectomy, ET Linked to Lower LRR in Young Populations With Breast Cancer

Revolution Medicines previews ‘novel class’ of cancer treatments

AACR in 30 Seconds: Revolution Medicines data, NCI director, wildfires

HDAC8 inhibition targets STAT3–MYC axis and synergizes with Venetoclax in KMT2A-rearranged acute myeloid leukemia

Mastectomy, ET Linked to Lower LRR in Young Populations With Breast Cancer

Revolution Medicines previews ‘novel class’ of cancer treatments

Latest Post

AACR in 30 Seconds: Revolution Medicines data, NCI director, wildfires

HDAC8 inhibition targets STAT3–MYC axis and synergizes with Venetoclax in KMT2A-rearranged acute myeloid leukemia

Mastectomy, ET Linked to Lower LRR in Young Populations With Breast Cancer

Subscribe to Updates

What's Hot

Browsing: Zenocutuzumab